The amount of the deal was not disclosed.
The investment will support the company’s R&D as well as commercialization of cardiac valve products.
Led by General Manager Zi Zhenjun, Venus Medtech has developed the Venus A-Valve, with independent intellectual property rights, a transcatheter aortic valve solution meeting China Food and Drug Administration clinical requirement.
In addition to Venus A-Valve, the company is advancing the transcatheter pulmonary artery valve, Venus P-Valve, which has also entered clinical stage. Venus P-Valve is designed for interventional therapy for patients with severe pulmonary regurgitation following surgery to repair Tetralogy of Fallot. Enrollment of patients for a clinical trial is nearly completed.
Venus Medtech plans to start patient enrollment for a pending EU approval-oriented clinical research program in the first half of 2016.
The company is also backed by Qiming Venture Partners, Sequoia Capital China, and Dinova Venture Capital.